老年人高血压强化降压治疗试验
STEP为多中心随机对照试验,纳入中国60~80岁高血压患者8511例,强化组目标收缩压110~<130 mmHg,标准组130~<150 mmHg。中位随访3.34年,主要复合终点(卒中、急性冠脉综合征、急性失代偿性心衰、冠脉血运重建、房颤或心血管死亡)发生率强化组3.5% vs 标准组4.6%(HR 0.74,95%CI 0.60~0.92,P=0.007)。卒中、急性冠脉综合征、急性失代偿性心衰HR均 favoring 强化治疗;安全性与肾脏结局两组无显著差异,但强化组低血压发生率更高。
要点
- 60~80岁中国高血压患者,强化组收缩压目标110~<130 mmHg,标准组130~<150 mmHg。
- 主要复合终点:强化组3.5% vs 标准组4.6%,HR 0.74(95%CI 0.60~0.92,P=0.007)。
- 卒中HR 0.67(95%CI 0.47~0.97),急性冠脉综合征HR 0.67(95%CI 0.47~0.94)。
- 急性失代偿性心衰HR 0.27(95%CI 0.08~0.98),强化治疗显著降低。
- 安全性与肾脏结局两组无显著差异,但强化组低血压发生率更高。
适用人群与场景
- 中国60~80岁高血压患者,纳入8511例,多中心随机对照试验。
- 原文未提及急诊、ICU或院前场景的适用人群。
诊断标准与关键阈值
- 强化治疗组收缩压目标为110~<130 mmHg;标准治疗组为130~<150 mmHg。
处置流程与药物剂量
- 第一步:将60~80岁高血压患者随机分配至收缩压目标110~<130 mmHg(强化治疗)或130~<150 mmHg(标准治疗)。
- 第二步:随访至1年时,强化组平均收缩压127.5 mmHg,标准组135.3 mmHg。
- 原文未提及具体药物名称、剂量、给药途径、频次或疗程。
红旗征与不能漏的情况
- 强化治疗组低血压发生率高于标准治疗组,需监测低血压。
- 原文未提及其他需立刻处理或不能漏诊的情况。
研究设计与关键结果
- 多中心、随机、对照试验,筛查9624例,纳入8511例(强化组4243例,标准组4268例),中国60~80岁高血压患者。
- 主要终点为卒中、急性冠脉综合征(急性心肌梗死和不稳定型心绞痛住院)、急性失代偿性心衰、冠脉血运重建、房颤或心血管死亡的复合终点。
- 中位随访3.34年,主要终点事件强化组147例(3.5%)vs 标准组196例(4.6%),HR 0.74(95%CI 0.60~0.92,P=0.007)。
- 卒中HR 0.67(95%CI 0.47~0.97);急性冠脉综合征HR 0.67(95%CI 0.47~0.94);急性失代偿性心衰HR 0.27(95%CI 0.08~0.98);冠脉血运重建HR 0.69(95%CI 0.40~1.18);房颤HR 0.96(95%CI 0.55~1.68);心血管死亡HR 0.72(95%CI 0.39~1.32)。
- 安全性与肾脏结局两组无显著差异,但强化组低血压发生率更高。
证据类型、等级与局限
- 证据类型:多中心随机对照试验(RCT)。
- 局限:原文未明确列出;研究对象为中国60~80岁高血压患者,外推需谨慎。
对床旁实践的改变
- 对60~80岁高血压患者,可考虑将收缩压目标设为110~<130 mmHg以降低心血管复合终点风险,但需警惕低血压发生率增加。
- 原文未提及急诊或ICU场景的具体实践改变。
指南或共识出处
- 原文未提及指南或共识名称;试验注册号NCT03015311,资助方为中国医学科学院等。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The appropriate target for systolic blood pressure to reduce cardiovascular risk in older patients with hypertension remains unclear.
METHODS: In this multicenter, randomized, controlled trial, we assigned Chinese patients 60 to 80 years of age with hypertension to a systolic blood-pressure target of 110 to less than 130 mm Hg (intensive treatment) or a target of 130 to less than 150 mm Hg (standard treatment). The primary outcome was a composite of stroke, acute coronary syndrome (acute myocardial infarction and hospitalization for unstable angina), acute decompensated heart failure, coronary revascularization, atrial fibrillation, or death from cardiovascular causes.
RESULTS: Of the 9624 patients screened for eligibility, 8511 were enrolled in the trial; 4243 were randomly assigned to the intensive-treatment group and 4268 to the standard-treatment group. At 1 year of follow-up, the mean systolic blood pressure was 127.5 mm Hg in the intensive-treatment group and 135.3 mm Hg in the standard-treatment group. During a median follow-up period of 3.34 years, primary-outcome events occurred in 147 patients (3.5%) in the intensive-treatment group, as compared with 196 patients (4.6%) in the standard-treatment group (hazard ratio, 0.74; 95% confidence interval [CI], 0.60 to 0.92; P = 0.007). The results for most of the individual components of the primary outcome also favored intensive treatment: the hazard ratio for stroke was 0.67 (95% CI, 0.47 to 0.97), acute coronary syndrome 0.67 (95% CI, 0.47 to 0.94), acute decompensated heart failure 0.27 (95% CI, 0.08 to 0.98), coronary revascularization 0.69 (95% CI, 0.40 to 1.18), atrial fibrillation 0.96 (95% CI, 0.55 to 1.68), and death from cardiovascular causes 0.72 (95% CI, 0.39 to 1.32). The results for safety and renal outcomes did not differ significantly between the two groups, except for the incidence of hypotension, which was higher in the intensive-treatment group.
CONCLUSIONS: In older patients with hypertension, intensive treatment with a systolic blood-pressure target of 110 to less than 130 mm Hg resulted in a lower incidence of cardiovascular events than standard treatment with a target of 130 to less than 150 mm Hg. (Funded by the Chinese Academy of Medical Sciences and others; STEP ClinicalTrials.gov number, NCT03015311.).
参考来源
- Zhang W, Zhang S, Deng Y, et al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med. 2021. PMID: 34491661. doi:10.1056/NEJMoa2111437
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。